Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Morepen Laboratories has informed that the company has successfully completed the first phase of its manufacturing capacity expansion program ahead of the previously indicated timeline. Under this first phase, the Company’s installed reactor capacity for API and CDMO has increased from 535 KL to 614 KL. This capacity enhancement strengthens the Company’s manufacturing readiness for the ongoing scale-up of commercial CDMO supplies, while also supporting its existing API business and future customer programs. This represents an important milestone in Morepen’s strategy to build a larger, scalable and globally compliant manufacturing platform, focused on long-duration customer partnerships and sustained growth across its API and CDMO businesses.
The above information is a part of company’s filings submitted to BSE.
